Across TCGA pan-cancer cohorts, YTHDF2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated YTHDF2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher YTHDF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated YTHDF2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

READ, BLCA, and PRAD are the cancer types where YTHDF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	III,IV	0.330	0.900	<.001	24	view →
BLCA	OS	Median	II,III,IV	1.000	0.706	.014	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: YTHDF2 tumor-vs-normal RNA expression · all YTHDF2 data types